AMG 193 Shows Preliminary Clinical Activity in MTAP-Deleted Solid Tumors - OncLive
AMG 193, an MTA-cooperative PRMT5 inhibitor, showed responses in patients with MTAP-deleted solid tumors, with an acceptable safety profile. The phase 1 trial results, presented at the 2024 ESMO Congress, revealed partial responses and stable disease across various tumor types, including NSCLC, pancreatic ductal adenocarcinoma, biliary tract cancer, and esophageal/gastric cancer. AMG 193 targets MTAP-deleted tumors selectively, avoiding normal cells, and preliminary data suggest potential for delayed responses and clinical benefit beyond partial responses.
Related Clinical Trials
Reference News
AMG 193, an MTA-cooperative PRMT5 inhibitor, showed responses in patients with MTAP-deleted solid tumors, with an acceptable safety profile. The phase 1 trial results, presented at the 2024 ESMO Congress, revealed partial responses and stable disease across various tumor types, including NSCLC, pancreatic ductal adenocarcinoma, biliary tract cancer, and esophageal/gastric cancer. AMG 193 targets MTAP-deleted tumors selectively, avoiding normal cells, and preliminary data suggest potential for delayed responses and clinical benefit beyond partial responses.